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I Abstract I Introduction 
The abuse of the designer amphetamines such as 3,4- 
methylenedioxymethamphetamine (MDMA, Ecstasy) is increasing 
throughout the world. They have become popular drugs, especially 
at all-night techno dance parties (Raves), and their detection is 
becoming an important issue. Presently, there are no MDMA- or 
MDA-specific immunoassays on the market, and detection of the 
designer amphetamines is dependent upon the use of commercially 
available amphetamine assays. The success of this approach has 
been difficult to assess because of the general unavailability of 
significant numbers of samples from known drug users. The 
objectives of the present study are to characterize the drug content 
of urine samples from admitted Ecstasy users by chromatographic 
methods and to assess the ability of the available 
amphetamine/methamphetamine immunoassays to detect 
methylenedioxyamphetamines.We found that, when analyzed by 
high-performance liquid chromatography with diode-array 
detection (HPLC-DAD), 64% of 70 urine samples (by gas 
chromatography-mass spectrometry [GC-MS]: 88% of 64 urine 
samples) obtained from Rave attendees contained MDMA and/or 
3,4-methylenedioxyamphetamine (MDA) alone or in combination 
with amphetamine, methamphetamine, or other designer 
amphetamines such as 3,4-methylenedioxyethylamphetamine 
(MDEA). This suggests that the majority of the Ravers are multi- 
drug users. At the manufacturer's suggested cutoffs, the Abbott 
TDx Amphetamine/Methamphetamine II and the new Roche HS 
Amphetamine/MDMA assays demonstrated greater detection 
sensitivity for MDMA than the other amphetamine immunoassays 
tested (Abuscreen OnLine Hitachi AMPS, Abuscreen OnLine 
Integra AMPS, Abuscreen OnLine Integra AMPSX, CEDIA AMPS, 
and EMIT II AMPS). There is 100% agreement between each of the 
two immunoassays with the reference chromatographic methods, 
HPLC-DAD and GC-MS, for the detection of 
methylenedioxyamphetamines. 
* Author to whom correspondence should be addressed. 
E-maik salvatore,salamone@roche.com. 
The amphetamine analogues of 3,4-methylenedioxyphenyl- 
alkylamines are a series of compounds referred to as designer 
amphetamines. As represented in Figure 1, these psychotropic 
drugs are ring-substituted derivatives chemically related to 
mescaline (1). They include 3,4-methylenedioxyamphetamine 
(MDA), 3,4-methylenedioxymethamphetamine (MDMA, 
Ecstasy), 3,4-methylenedioxyethylamphetamine (MDEA), 
3,4-methylenedioxyphenyl-2-butanamine (BDB), and N-methyl- 
1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB). 
MDMA is the most commonly known designer drug. After 
cannabis, it is the most abused illicit drug generally used at all- 
night techno dance parties (Raves) in Europe. It has been re- 
ported that 97% of the analyzed so-called Ecstasy preparations 
(pills, capsules, powders) contain a single active substance (2). 
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Figure 1. Structures of amphetamines and 3,4-methylenedioxyam- 
phetamines. 
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Of these specimens, 47.5% contained MDMA, 42.7% MDEA, 
6.5% amphetamine (AMP), and 0.3% MDA and MBDB. These 
samples also include excipients for tableting and sometimes 
other pharmaceutical agents (e.g., caffeine). 
The 3,4-methylenedioxyamphetamines (MDAMPS) are re- 
ported to enhance understanding, communicativeness, and 
empathy, almost without showing hallucinogenic effects (3,4). 
They are described as "entactogens', which is a new drug class 
different from the hallucinogenic phenylalkylamines (5). The 
mechanism of activity of MDMA is characterized by a high 
affinity at serotonin uptake sites. In animal experiments, MDMA 
has shown dose- and species-dependent neurotoxic effects on 
central serotonergic neurons in terms of degeneration of axon 
terminals (6-13). 
Several animal and human studies have shown that MDMA is 
metabolized by demethylenation, N-demethylation, deamina- 
tion, O-methylation, and O-conjugation to glucuronide and/or 
sulfate metabolites (14-21). The parent drug is mainly detected 
in urine, and the conjugates of 4-hydroxy-3-methoxymetham- 
phetamine (HMMA) and 3,4-dihydroxymethamphetamine 
(HHMA) are the dominating metabolites. Minor metabolites are 
4-hydroxy-3-methoxyamphetamine (HMA), 3-hydroxy-4- 
methoxymethamphetamine, 4-hydroxy-3-methoxyphenylace- 
tone, 3,4-methylenedioxyphenylacetone, and 3,4-dihydroxy- 
phenylacetone. Most of these compounds are also present in the 
blood, with HMMA glucuronide as the major conjugated 
metabolite and MDA as the major unconjugated metabolite 
(21). MDA is also a metabolite of MDEA (22). 
~pically, MDMA and MDEA are sold in the racemic form. The 
enantiomers are different in respective to pharmacokinetics 
and pharmacodynamics (23-25). Several studies have evaluated 
the enantioselective metabolism and disposition of these com- 
pounds (26-32). As reported from mice and rat studies on 
racemic MDMA, I-MDMA and d-MDA were the predominant 
enantiomers in 24-h pooled urine. Although administration of 
racemic MDEA resulted in greater excretion of the d-enan- 
tiomer of MDEA, d-MDA was present in greater amounts than 
I-MDA in all of those samples except blood where the enan- 
Table I. Retention Times and Ions Monitored for all 
Amphetamines Tested by GC-MS 
Retention Ions monitored [m/z] 
Compound time (min) (quantitation ion underlined) 
Amphetamine 8.15 240, 118 
Amphetamine-d6 8.08 244, 123 
Methamphetamine 10.46 254, 210, 118 
Methamphetamine-d9 10.34 261,213 
MDA 15.02 375,240 
MDA-ds 14.99 380, 244 
MDMA 16.42 254, 210, 389 
MDMA-ds 16.39 ~ 213, 294 
MDEA 16.75 162, 268, 240 
MBDB 16.99 ~ 176, 210 
Epedrine 10.62 254, 210 
Pseudoephedrine 11.73 254, 210 
Phenylpropanolamine 9.17 240, 330 
Phentermine 8.45 ~ 91 
tiomers were present in equal amounts. In another report, I- 
MDMA and I-MDA exceeded the respective d-enantiomers 
within the first 36-h postdose (33). Greater amounts of I-MDMA 
than d-MDMA were observed in bile, blood, liver, urine, and vit- 
reous humor in samples collected at autopsy in a case of fatal 
poisoning (31). 
Urine and blood are the most commonly studied biological 
matrices for MDMA, MDA, MDEA, and MBDB and are well doc- 
umented in the literature. Determination of these designer 
drugs in other biological specimens such as saliva, sweat, and 
hair has been reported more recently (34). The parent drug is 
detected in higher concentrations than its metabolites in these 
matrices. 
In urine, the MDAMPS can be measured by gas chromatog- 
raphy-mass spectrometry (GC-MS) using the same methods 
presently employed for the analysis of AMP and metham- 
phetamine (MAMP). The enantiomers of MDA, MDMA, MDEA, 
AMP, and MAMP were reported to be determined simultane- 
ously in human urine using liquid-liquid extraction followed by 
derivatization with trifluoroacetyl-l-propyl chloride (I-TPC) and 
analysis by GC-MS (33). High-performance liquid chromatog- 
raphy (HPLC) with electrochemical, UV, or diode-array detec- 
tion (DAD) has been used for the detection of MDMA in 
biological specimens (14,19,32,35-37). GC-MS analysis is 
highly specific and is used for the confirmation of positive im- 
munoassay results or a suspected diagnosis. 
The abuse of these MDAMPS is increasing throughout the 
world, and their detection by screening methods is becoming a 
more important issue. There are currently no commercial im- 
munoassays designed specifically for the detection of these 
substances, and their detection therefore depends on the rela- 
tive cross-reactivities they exhibit in the AMP or MAMP 
screening method used. In general, the cross-reactivity of the 
commercially available AMP and MAMP assays toward many of 
these compounds is low, which suggests the possibility that 
some positive samples may go undetected. The potential for this 
has been difficult to assess because of the general unavailability 
of significant numbers of samples from known drug users. 
The present study reports on the ability of a number of com- 
mercially available immunoassays to detect samples obtained 
from a population of people using MDAMPS at Raves. It also 
evaluates the new Abuscreen OnLine HS AMP/MDMA assay, 
which is specifically designed to increase the detection sensi- 
tivity for the use of MDMA. The sensitivities of the immuno- 
assays are assessed relative to GC-MS and HPLC-DAD. 
Experimental 
Urine sampling 
Seventy urine specimens (50-100 mL) were collected from 
anonymous Ecstasy users (self-declared in the interview prior to 
urine sampling) at two major Raves in Zurich (Switzerland) in 
December 1997 at the "Limmat House" and August 1998 at the 
"Red Fabric" with the permission of the Ethics Committee of the 
University of Bern. The time of collection was 1-8 h after con- 
sumption. The urines were kept frozen at -80~ until analysis. 
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Instrumentation and reagents 
Imraunoassays. The Abbott TDx AMP/MAMP II (TDx AMPS) 
reagents were purchased from Abbott Laboratories (Abbott 
Park, IL) and used on an Abbott Axsym analyzer. The Emit II 
AMP/MAMP assay (EMIT II AMPS) was purchased from Behring 
Diagnostics (San Jose, CA) and used on a Cobas Mira analyzer 
(Roche). The CEDIA DAU AMPS (Cedia AMPS) assay was pur- 
chased from Microgenics (Pleasanton, CA) and used on a Hi- 
tachi 917. Five different Roche Abuscreen OnLine (KIMS) 
formats were used. These were the standard OnLine reagents 
(AMPS) used on a Roche Hitachi 747; the standard Integra ver- 
sion reagents (AMPS) used on a Roche Integra 700; the stan- 
dard OnLine Integra reagent using a high-sensitivity MDMA 
application (AMPSX) on the Integra 700 at both 500- and 1000- 
ng/mL cutoffs; and the recently developed OnLine HS 
AMP/MDMA assay with greater sensitivity for the designer AMP 
analogues using a Hitachi 917. All immunoassays were prepared 
and used according to the instructions provided by the manu- 
facturer for the specified instrument (38-44). All irnmunoassays 
use a 1000-ng/mL cutoff with the exception of the OnLine HS 
AMP/MDMA assay (300-ng/mL cutoff) and the OnLine Integra 
AMPSX (500- and 1000-ng/mL cutoffs). CEDIA assays for drugs- 
of-abuse screening panel were used for identification of other 
drugs in the specimens. TDx AMPS, the CEDIA AMPS, and 
Abuscreen OnLine AMPS assays (Hitachi and Integra) were 
calibrated with d-AMP calibrator from ~e respective manufac- 
turers. The EMIT II AMPS was calibrated with d-MAMP cali- 
brator (Behring). The HS AMP/MDMA assay was calibrated with 
the Preciset d,I-MDMA Calibrators (Roche). 
GC-MS analysis. GC-MS analysis was performed on a 
Hewlett-Packard (HP) 5890 GC interfaced with an HP 5970 
MS. The GC column was a DB-5 (25 m x 0.2 ram, 0.33-1Jm film 
thickness). The GC column was operated at an initial temper- 
ature of 120~ for 2 rain, programmed to 180~ at 5~ 
and then to 250~ at 20~ with a final temperature hold 
for 4 min. Urine extractions were performed with chloroform 
under basic conditions. Heptafluorobutyric anhydride (HFBA) 
(Aldrich) was used to derivatize MDMA, MDEA, MDA, and other 
AMP-related compounds for GC-MS analysis. Deuterated in- 
ternal standards (AMP-d6, MAMP-dg, MDA-ds, and MDMA-ds) 
were added to all calibrators, negative and positive controls, and 
samples. The calibration curve was spiked with all drugs of in- 
terest: AMP, MAMP, MDA, MDMA, MDEA, MBDB, EPH, pseu- 
doephedrine, phenylpropanolamine (PPA), and phentermine. 
The retention times and ions monitored for the different ana- 
lytes are shown in Table I. Identification of the individual drugs 
in the urine samples is based on having the proper ion ratios 
(within + 20% of those of the standards) and the proper reten- 
tion times (within + 2% of those of the standards). At least two 
ions were monitored for each analyte (one ion ratio) and in 
some cases three ions (two ion ratios) were monitored. The 
limit of quantitation of AMP and MAMP was 50 ng/mL and 25 
ng/mL for the other analytes mentioned here. 
HPLC-DAD analysis. The HPLC system consisted of an HP 
1090M liquid chromatograph with an HP 1040M DAD and an 
HP HPLC Chemstation. The separation was performed gradi- 
ently at 40~ on a 150 x 4.6-ram internal diameter column with 
a 20 x 4-mm internal diameter precolumn packed with 3-1~m 
Spherisorb C-18 ODS-1. The mobile phase was (A) water con- 
taining 8.5 g H3PO4 (85%) and 280 IJL hexylamine and (B) a 
mixture of 702 mL acetonitrile and 91.6 mL water containing 
8.5 g H3PO4 (85%) and 280 IJL hexylamine per liter. The gra- 
dient program was as follows: 0-12 min, 0-15% B; 12-15 rain, 
15% B; 15-20 min, 15-35% B; 20-25 min, 35-36% B; 25-28 
rain, 36% B; 28-32 rain, 36-50% B; 32-35 min, 50% B; 35-45 
min, 50-0% B; 45-75 rain, 0% B. The flow rate was 150 
IJL/min; the injection volume was 1 lJL. Peak identification 
was performed by DAD at 198--300 nm and by library match; 
quantitation was performed at 198 nm by measuring the peak 
areas versus internal standard. Sample preparation was con- 
ducted as follows: the unhydrolyzed urine specimens were ex- 
tracted by solid-phase extraction (SPE) according to a method 
published previously (19) with the exception that instead of 
MAMP mescaline was used as internal standard. Pseu- 
doephedrine, PPA, and phentermine were not measured. 
REMEDi TM HPLC analysis. The Rapid Emergency Drug Iden- 
tification System (REMEDi, Bio-RAD Laboratories) is an auto- 
mated drug-profiling system consisting of multicolumn HPLC 
with fast-scanning spectrophotometric detection. It allows a 
broad screening of more than 500 drugs and was used ac- 
cording to the manufacturer's instructions and a method pub- 
lished previously (45). 
Results and Discussion 
Immunoassay screening and evaluation of the sensitivity of 
commercial amphetamine assays for MDMA 
Urine samples from Ecstasy users were tested by the com- 
mercial AMPS immunoassays at respective manufacturers' 
mandated cutoffs. Most were run at a 1000-ng/mL cutoff with 
the exception of the Abuscreen OnLine HS AMP/MDMA assay 
(300-ng/mL cutoff). Integra AMPSX was evaluated at both a 
1000- and 500-ng/mL cutoffs using the same set of parameters 
and calibrators. 
In general, as shown in Tables II-IV, the immunoassays ex- 
hibit a good sensitivity for MDMA containing drugs as com- 
pared to the chromatographic methods, HPLC-DAD and 
GC-MS. In each case, the immunoassay positive screening rate 
was calculated based on the screened positives versus total pos- 
itives confirmed by the GC-MS or HPLC-DAD reference 
method at a 300-ng/mL cutoff. Some samples could not be 
tested by all the assays because of the limited sample volume. 
The positive-screening sensitivity of these immunoassays for 
MDAMPS (see Table IV) was in the following descending order: 
Abuscreen OnLine HS AMP/MDMA (300-ng/mL cutoff) > TDx 
AMPS (1000-ng/mL cutoff) > OnLine Integra AMPSX (500- 
ng/mL cutoff) > OnLine Hitachi AMPS (1000-ng/mL cutoff) > 
OnLine AMPSX (1000-ng/mL cutoff) ~ CEDIA AMPS (1000- 
ng/mL cutoff) > EMIT II AMPS (1000-ng/mL cutoff) > OnLine 
Integra AMPS (1000-ng/mL cutoff). The corresponding rates 
were 100, 98, 96, 92, 87, 87, 86, and 84%. The 13 samples (nos. 
7, 16, 17, 27, 33, 34, 54, 57, 58, 62, 64, 65, 70) analyzed positive 
by the reference methods (GC-MS and/or quantitative 
HPLC-DAD) and negative by at least one immunoassay using 
a 300-ng/mL cutoff are noted in Table V. 
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One major cause for the variation in the positive-screening 
sensitivity is the difference in cross-reactivity to MDMA and 
other MDAMPS in these assays. As summarized in Table VI, the 
information in the literature (46) and the respective manufac- 
turer's inserts (38-44) indicate a large difference in cross-re- 
activities to these substances. The cross-reactivity to MDMA 
ranged from 97 to 0.2%. The cross-reactivity to MDA ranged 
from 148 to 1.9%. The sensitivity of most immunoassays to 
MDA is less than 40% except for TDx AMPS (148%). Moreover, 
both Abuscreen OnLine HS AMP/MDMA and TDx AMPS have 
demonstrated higher cross-reactivity with MBDB, which is less 
neurotoxic than MDMA and increasingly abused (46). In addi- 
tion, the cross-reactivity to other AMP-like medications such as 
EPH and PPA seems not to increase significantly as the cutoff 
of an assay decreases. 
Higher detection sensitivity for MDAMPS is available with the 
TDx AMPS and Abuscreen OnLine HS AMP/MDMA assays. This 
is demonstrated by the results obtained with the 10 samples 
(nos. 1, 5, 7, 15, 27, 33, 34, 47, 59, 66) containing only MDMA 
and/or MDA when analyzed by the reference methods (GC-MS 
or quantitative HPLC-DAD) and using a 300-ng/mL cutoff. As 
shown in Table VII, the positive-screening rate for MDMA/MDA 
Table V. Discrepant Samples Tested by Instrumental Immunoassays, HPLC, and GC-MS using a 300-ng/mL Cutoff 
Abuscreen OnLine EMIT II TDx Cedia HPLC 
Sample AMPS *,+ AMPSX* AMPS* HS AMP/MDMA ~ AMPS* AMPS* AMPS* Quant. HPLC-DAD GC-MS 
no. Integra 700 Integra 700 Hitachi 747 Hitachi 917 Cobas Mira Axsym Hitachi 917 (ng/mL) (rig/rot) 
7 neg pos pos pos (>AMAX) pos pos pos 4720 MDMA 96 MDA, 
8944 MDMA 
16 pos pos pos pos (>AMAX) neg pos pos 9500 AMP 11240 AMP, 
79 PPA 
17 neg neg pos pos (>AMAX) pos pos neg neg 715 AMP 
27 neg ne 8 pos pos (>AMAX) neg pos pos 3098 MDMA 2384 MDMA 
33 neg neg neg pos neg pos neg 816 MDMA n.a. 
34 neg neg neg pos (>AMAX) neg pos neg 887 MDMA n.a. 
54 ne 8 neg n.a. pos neg neg neg neg 404 AMP 
57 neg neg n.a. pos (>AMAX) neg pos neg 159 MDA 142 AMP, 
424 MDA 
58 pos pos n.a. pos (>AMAX) pos neg pos 2781 AMP, 555 AMP, 439 MDA, 
1923 MDMA 4417 MDMA 
62 neg neg n.a. pos (>AMAX) neg pos neg 780 AMP, 
1700 MDA 482 AMP, 615 MDA 
64 pos pos n.a. pos (>AMAX) neg pos neg 1200 AMP 969 AMP 
65 pos pos n.a. pos (>AMAX) pos pos neg 740 AMP, 398 AMP, 
1200 MDMA 1277 MDMA 
70 neg neg n.a. pos (>AMAX) neg pos neg 111 MDMA 195 AMP, 
545 MDMA 
* Cutoff, 1000 nglmL. 
Abbreviations: >AMAX, > 600 nglmL (highest calibrator); n.a., not analyzed; AMP(S), amphetamine(s); BD, benzodiazepines; CANN, cannabinoids; COC, cocaine; EPH, 
ephedrine; MAMP, methamphetamine; MDA, 3,4-methylenedioxyamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MDEA, 3,4-methylenedioxyethylamphetamine; 
METH, methadone; OP, opiates; and PPA, phenylpropanolamine. 
Cutoff, 300 ng/mL. 
Table VI. Cross-Reactivities* of Commercial AMPS Immunoassays for the Detection of MDAMPS 
Abuscreen OnLine 
AMPSX Integra Abuscreen OnLine 
and AMPSX 500 + Abuscreen OnLine AMPS Hitachi Abuscreen OnLine TDx AMPS Cedia AMPS EMIT II AMPS 
Compound (MDMA sensitive) AMPS Hitachi 500 + 1000 + HS AMP/MDMA 300 + 1000 + 1000 + 1000 + 
MDMA 79 36 0.2 90 97 69 16 
MDA 40 36 35 22 148 1.9 33 
MDEA n.a.* n.a. n.a. 11 43 24 n.a. 
MBDB n.a. n.a. n.a. 64 (+) n.a. (low) 
BDB n.a. n.a. n.a. 4 (+) n.a. (low) 
I-EPH < 0.1 < 0.1 < 0.2 0.3 < 0.3 0.4 0.5 
/-PPA 1.1 1.5 1 0.6 < 0.1 0.3 0.3 
* Values (%) according to literature (46) and respective manufacturer's package inserts (38-44). 
~" Cutoff (nglmL). 
Not analyzed. 
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was in the following descending order: Abuscreen OnLine HS 
AMP/MDMA ~ TDx AMPS > CEDIA AMPS > Abuscreen On- 
Line AMPS (Hitachi) > Abuscreen OnLine AMPSX (Integra) > 
EMIT II AMPS > Abuscreen OnLine AMPS (Integra). Two spec- 
imens (nos. 40, 52) containing MDA concentrations below 300 
ng/mL by GC-MS were negative by all immunoassays. 
Table VII. Positive Screening Rate for MDMA and MDA Using Commercial 
AMPS Immunoassays at Respective Cutoffs 
No. of samples tested positive by 
Immunoassay immunoassay/reference methods 
The OnLine assays at different cutoffs exhibit a large range of 
cross-reactivities to MAMP and its structurally related ana- 
logues, MDMA, MDEA, and MBDB (Table VI). At the 1000- 
ng/mL cutoff for the Hitachi application, the cross-reactivity 
with MAMP is less than 2%, whereas at the 500-ng/mL cutoff, 
the cross-reactivity is significantly increased to 80%, which is 
similar to that of AMP. This is partly at- 
tributable to the use of a different set of in- 
strument parameters. This phenomenon 
contributes to the increase in detected positive 
specimens at the lower cutoffs. 
Rate (%)* Lowering the cutoffs of the existing com- 
mercial AMP assays below 1000 ng/mL will in- 
60 crease the detectability for AMP and its 
analogues significantly. However, the number 
7o of positive results from those samples con- 
taining high concentrations of AMP-related 
71 medications such as I-MAMP and the [3-hy- 
droxyphenylethylamines would also increase. 
100 Therefore, assays for MDAMPS should be de- 
67 signed and assessed for maximum positive 
100 screening rate (sensitivity) and for minimum 
80 cross-reactivity with other medications such as 
EPH, pseudoephedrine, phentermine, and 
tyramine. These medications are usually taken 
at high doses. Pragmatically, an AMP or MAMP 
assay should be developed with high cross-re- 
activity to MDMA and/or other MDAMPS in- 
stead of developing MDAMPS-specific assays. 
By following this design strategy for the selec- 
tion of antibodies, the potential false positives 
derived from AMP-related medications would 
Other t be decreased or eliminated. 
Abuscreen OnLine 6 / 10 
AMPS (Integra) 
Abuscreen OnLine 7 / 10 
AMPSX (Integra) 
Abuscreen OnLine 5 / 7 
AMPS (Hitachi) 
Abuscreen OnLine HS 10 / 10 
AMP/MDMA 
EMIT II AMPS 6 /9  
TDx AMPS 10/10 
Cedia AMPS 8 / 10 
* Calculated by the number of samples tested positive by immunoassay versus those tested positive for MDMA 
and/or MDA with the reference methods (GC-MS or quantitative HPLC-DAD) at a 300-ng/mL cutoff. 
Table VIII. Distribution of Positive Samples Containing Multiple AMP 
Analogues and Other Drugs of Abuse at Rave Parties 
Number of 
samples tested Number of samples also tested positive for...* 
Compound positive for...* AMP MAMP MDMA MDA MDEA PPA, EPH 
AMP 47 2 33 24 5 21 28 
MAMP 2 2 1 1 0 1 2 
MDMA 40 33 1 28 5 18 26 
MDA 32 24 1 28 5 13 23 
MDEA 5 5 0 5 5 3 4 
PPA, EPH 22 21 1 18 13 3 13 
Other * 37 28 2 26 23 4 13 
= Results according to GC-MS analysis (64 samples analyzed). 
f Benzodiazepines, cannabis, cocaine, LSD, methadone, and/or opiates (Cedia DAU). 
Table IX. Correlation of HPLC with GC-MS* 
Correlation (%) 
Positive samples 
Method Cutoff (ng/mt) Yes No 
Negative samples 
Yes No 
GC-MS 300 100 0 100 
HPLC-DAD 300 75 25 100 
REMEDi - 62 38 82 
GC-MS 100 100 0 100 
HPLC-DAD 100 64 36 100 
REMEDi - 61 39 100 
* Related to the detection of amphetamines (AMP, MAMP) and MDAMPS (MDA, MDMA, MDEA) in 64 
samples. 
0 
0 
18 
0 
0 
0 
Drug-testing profile at Rave parties 
AMP alone or in combination with MDMA, 
MDEA, or MBDB was present in the urine of 
most Ecstasy users as indicated from this com- 
prehensive analysis of Rave samples by the 
chromatographic methods. As shown in Ta- 
bles II, III, V, and VIII, of 64 specimens ana- 
lyzed by GC-MS, 56 (88%) contained AMPS 
(AMP, MAMP) and/or MDAMPS (MDA, MDMA, 
MDEA). Thirty-five urine samples (55%) were 
tested positive for both AMPS and MDAMPS. 
AMP was detected in 47 (73%), MDMA in 40 
(63%), and MDA in 32 samples (50%). Five 
samples (8%) contained MDEA, and two sam- 
pies (3%) MAMP. Nine samples (14%) con- 
tained only MDMA and/or MDA. Eight samples 
(13%) were negative for AMP-like substances. 
A broad range of AMP analogues has also 
been detected on the Rave scene. Using 
REMEDi and GC-MS, licit compounds such as 
caffeine, quinine, dihydroergotamine, vera- 
pamil, EPH, PPA, etc. were detected in 31 
(44%) of the 70 samples. These substances 
may have been added to the Ecstasy pills as 
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adulterants or diluants or originated from drinks and medica- 
tions. Other classes of abused drugs were detected in 37 of 70 
samples (53%) using the CEDIA DAU assays and REMEDi. 
Thirty-one (44%) were positive for cannabis, seven (10%) were 
positive for cocaine, and three (4%) were positive for benzodi- 
azepines. Opiates, LSD, and methadone were detected in two 
(3%), two (3%), and one sample (1%), respectively, above the 
CEDIA DAU cutoff levels. It appears that the majority of the 
Ravers are multi-drug users, with cannabis as the dominating 
co-consumed drug. 
In this study, MDMA and MDA were considered as evidence of 
Ecstasy use. As reported (19), the MDMA concentration in urine 
climbs after at least 4 h postadministration. Peak concentration 
of MDMA in urine is usually reached at 21.5 h. Because the sam- 
ples used in this study were collected randomly between i and 
8 h after administration, the absence of MDMA in some samples 
may partly represent samples collected within 2 h of adminis- 
tration. HMMA (as glucuronide) is reported to be the major uri- 
nary metabolite of MDMA present in much higher 
concentration than MDA and HMA. MDA and HMA are formed 
upon further metabolism. The peak excretion period for HMMA 
is from 5 to 21.5 h (19). The AMPS immunoassays are not de- 
signed to detect this type of ring-opened metabolite, and the 
cross-reactivity to these compounds is low. Screening and con- 
firmation for HMMA may offer improved detection rate. Further 
characterization of the HMMA content in these samples by 
chromatographic methods will help to answer these MDMA 
abuse questions in Ravers. 
The positive urine specimens in this study generally exhibit 
concentration ratios of MDA to MDMA of less than 0.15. Only 
two samples (nos. 42, 43) had values greater than 0.2. The 
ratio of MDA to MDMA in human urine has been reported to be 
indicative of either MDA abuse or MDA as the N-demethylation 
metabolite of MDMA (47). A ratio lower than 0.15, which is the 
metabolic ratio of MDA to MDMA in humans, suggests a higher 
probability of MDMA abuse (MDA absence in original prepara- 
tion). In contrast, when the ratio is greater than 0.15, there is 
a higher probability of MDA abuse in addition to MDMA abuse. 
The low ratio of MDA to MDMA suggests that MDMA was taken 
in the scene. 
Most specimens have been found to contain high to extremely 
high concentrations of AMP and MDAMPS. The mean concen- 
trations of AMP, MDMA, MDA, and MDEA were 9.8 I~g/mL 
(0.19-65 ~g/mL, n = 43, HPLC quantitation), 19.2 ~g/mL 
(0.11-173 I~g/mL, n = 43), 1.4 lJg/mL (0.14-6.8 ~g/mL, n = 19), 
and 16.71Jg/mL (0.20-56 lJg/mL, n = 5), respectively. This sug- 
gests that these drugs were administered at high doses. In ad- 
dition, within the limited collection period (1-8 h), 
concentrations of parent drugs such as MDMA, MDEA, or MBDB 
would be higher than their respective metabolites in urine. 
Correlation of reference methods: HPLC versus GC-MS 
Chromatographic confirmation assays with MS, DAD, or fast- 
scanning UV detection (GC-MS, LC-MS, HPLC-DAD, REMEDi) 
are necessary to verify AMPS-positive immunoassay results and 
identify the drugs present. In general, the present study demon- 
strates a good correlation between GC-MS and quantitative 
HPLC-DAD analysis related to the detection of amphetamines 
(AMP, MAMP) and MDAMPS (MDA, MDMA, MDEA). At a cutoff 
of 300 ng/mL, a correlation was observed in 75 and 100% of 
positive and negative samples, respectively, whereas the corre- 
lation was 64 and 100% at the 100-ng/mL cutoff (Table IX). The 
two chromatographic reference methods exhibited mainly some 
discrepancies in the detection of drugs such as MDA and AMP 
at lower concentrations. For example, 16 samples negative for 
MDA and/or AMP by HPLC-DAD were positive for these com- 
pounds when analyzed by GC-MS using a 100 ng/mL cutoff (Ta- 
bles II and III). Retention times and ions used for GC-MS 
identification and quantitation are shown in Table I. At the 
300-ng/mL cutoff, only six samples were positive for MDA 
and/or AMP by GC-MS. This could be due to either the differ- 
ences in the extraction procedures and internal standards used 
by the two methods or the inability to detect 100 ng/mL of AMP 
or MDA by the HPLC-DAD method because of the limited de- 
tector sensitivity. With the qualitative HPLC REMEDi system, 
which is less often used for forensic than for clinical toxicology, 
the correlation rates were 60 and 61% for positive samples and 
73 and 88% for negative samples, respectively (Table IX). Nev- 
ertheless, HPLC has the potential as an alternative method to 
GC-MS for the detection of AMPS and MDAMPS. 
Conclusions 
This report describes a comprehensive analysis of samples 
collected from participants at Rave parties in Zurich, Switzer- 
land. By the combination of immunoassays and chromato- 
graphic methods, it was found that AMPS (AMP, MAMP) and/or 
their 3,4-methylenedioxy analogues (MDA, MDMA, and MDEA) 
were present in 89% of the samples. The majority of these 
samples (82%) contained MDMA and/or MDA. About one-half of 
the samples (53%) contained other classes of abused drugs, 
suggesting that a high percentage of Ravers are multi-drug 
users. The evaluation of a number of commercially available 
AMPS immunoassays demonstrated a generally good effective- 
ness for the detection of Ecstasy users. At the manufacturer's 
suggested cutoff, the Abuscreen OnLine HS AMP/MDMA and 
TDx AMPS assays have demonstrated higher detection sensi- 
tivity than the other commercial AMPS immunoassays tested 
(Abuscreen OnLine Hitachi AMPS, Abuscreen OnLine Integra 
AMPS, Abuscreen OnLine Integra AMPSX, CEDIA AMPS, and 
EMIT II AMPS). These two immunoassays were in total agree- 
ment using these samples and demonstrated the best correla- 
tion to the reference chromatographic methods, GC-MS and 
HPLC-DAD. This study also suggests that HPLC has the po- 
tential as an alternative method to GC-MS for the confirmation 
of methylenedioxyamphetamine-type drugs. 
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